Profile data is unavailable for this security.
About the company
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
- Revenue in USD (TTM)562.02m
- Net income in USD-293.25m
- Incorporated2015
- Employees--
- LocationTempus AI Inc600 West Chicago Avenue, Suite 510CHICAGO 60654United StatesUSA
- Fax+1 (302) 655-5049
- Websitehttps://www.tempus.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunovant Inc | 0.00 | -259.34m | 4.38bn | 207.00 | -- | 7.07 | -- | -- | -1.89 | -1.89 | 0.00 | 4.24 | 0.00 | -- | -- | 0.00 | -48.37 | -- | -52.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Nuvalent Inc | 0.00 | -145.51m | 5.20bn | 106.00 | -- | 7.69 | -- | -- | -2.41 | -2.41 | 0.00 | 10.47 | 0.00 | -- | -- | 0.00 | -24.88 | -- | -26.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 5.50bn | 28.00 | -- | 5.88 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 5.74bn | 376.00 | -- | 6.55 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Krystal Biotech Inc | 95.95m | 57.16m | 5.92bn | 229.00 | 110.15 | 7.40 | 93.34 | 61.70 | 1.88 | 1.88 | 3.38 | 28.02 | 0.1385 | -- | -- | 418,991.30 | 8.25 | -11.50 | 8.78 | -12.01 | 94.25 | -- | 59.57 | -492.85 | 12.42 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Summit Therapeutics Inc | 0.00 | -116.03m | 6.54bn | 105.00 | -- | 147.83 | -- | -- | -0.1657 | -0.1657 | 0.00 | 0.063 | 0.00 | -- | -- | 0.00 | -53.76 | -77.32 | -59.38 | -86.35 | -- | -- | -- | -20,989.46 | -- | -118.81 | 0.6934 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Exelixis Inc | 1.85bn | 205.05m | 6.56bn | 1.31k | 34.81 | 3.12 | 28.47 | 3.55 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Tempus AI Inc | 562.02m | -293.25m | 6.57bn | -- | -- | -- | -- | 11.69 | -1.78 | -1.78 | 3.41 | -2.06 | -- | -- | -- | -- | -- | -- | -- | -- | 54.25 | -- | -39.94 | -- | 1.13 | -16.02 | 4.19 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Cytokinetics, Inc. | 3.75m | -530.60m | 6.59bn | 423.00 | -- | -- | -- | 1,756.50 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 6.97bn | 373.00 | 22.65 | 39.16 | 17.38 | 8.07 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 7.00bn | 927.00 | -- | 23.59 | -- | 9.01 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 7.16bn | 645.00 | -- | 23.04 | -- | 25.37 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 7.66bn | 411.00 | -- | 4.44 | -- | 1,677.32 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.78bn | 355.00 | -- | 13.77 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 14 Jun 2024 | 9.37m | 5.86% |
| Nikko Asset Management Co., Ltd.as of 30 Jun 2024 | 72.00k | 0.05% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 2024 | 6.42k | 0.00% |
| Euromobiliare Asset Management SGR SpAas of 28 Jun 2024 | 1.38k | 0.00% |
